Intellia cuts 27% of staff

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...
Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025, emphasizing the acceleration of ...
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
These moves will enable the gene-editing company to focus resources on late-stage programs as it aims to launch a commercial product by 2027, it said.
Intellia Therapeutics will cut about 27% of its workforce, or roughly 142 jobs, this year in a cost-savings push intended to support its operations into the first half of 2027, when it expects to ...
Intellia Therapeutics (NTLA) announced a strategic reorganization focused on key value drivers. The pipeline prioritization is intended to ...
Shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) fell 2.4% in pre-open trading Friday as the company announced a strategic reorganization focusing on key valu ...
To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Intellia Therapeutics will stop work on one of its principal drug research programs and lay off more than ...